Research directory

Clinical trials for IBD

Below are clinical trials currently recruiting participants in the United States.

125 studies

Long-term mirikizumab study for young people with ulcerative colitis or Crohn's

A long-term study of mirikizumab in young people with ulcerative colitis or Crohn's disease who are continuing from specified earlier studies.

Crohn's Disease · Inflammatory Bowel Diseases · Ulcerative Colitis · Ulcerative Colitis Chronic

Phase: Phase 3
Age range: 2 Years–19 Years
Enrollment: 150 participants

68 recruiting sites

Updated Aug 24, 2026

Recruiting

NCT05509777

Mirikizumab for Children and Adolescents With Crohn’s Disease

A Phase 3 study of mirikizumab in children and adolescents ages 2–17 with moderately to severely active Crohn’s disease.

Crohn's Disease

Phase: Phase 3
Age range: 2 Years–17 Years
Enrollment: 90 participants

80 recruiting sites

Updated Aug 24, 2026

Recruiting

NCT07071519

Phase 3 Study of Risankizumab in Children With Ulcerative Colitis

A Phase 3 study of risankizumab in children ages 2 to 17 with moderately to severely active ulcerative colitis.

Ulcerative Colitis

Phase: Phase 3
Age range: 2 Years–17 Years
Enrollment: 120 participants

57 recruiting sites

Updated Aug 24, 2026

Recruiting

NCT07470879

Etrasimod study in children with moderately to severely active ulcerative colitis

A Phase 2 study of daily oral etrasimod in children ages 2–11 with moderately to severely active ulcerative colitis.

Colitis, Ulcerative

Phase: Phase 2
Age range: 2 Years–11 Years
Enrollment: 24 participants

42 recruiting sites

Updated Aug 24, 2026

Recruiting

NCT07483073

Phase 2 Study of Mirikizumab With or Without LY4395089 for UC or Crohn's

A randomized study of mirikizumab with or without LY4395089 in adults with moderately to severely active ulcerative colitis or Crohn's disease.

Colitis, Ulcerative · Crohn Disease

Phase: Phase 2
Age range: 18 Years–80 Years
Enrollment: 60 participants

68 recruiting sites

Updated Aug 24, 2026

Recruiting

NCT07483099

LY4395089 Plus Mirikizumab Versus Mirikizumab for Crohn's Disease

A Phase 2 study comparing LY4395089 plus mirikizumab with mirikizumab alone in adults with moderately to severely active Crohn's disease.

Crohn Disease

Phase: Phase 2
Age range: 18 Years–80 Years
Enrollment: 60 participants

69 recruiting sites

Updated Aug 24, 2026

Recruiting

NCT07683325

Ontunisertib or Placebo for Adults With Fibrostenosing Crohn's Disease

A Phase 2 study comparing three doses of ontunisertib with placebo in adults with symptomatic fibrostenosing Crohn's disease.

Fibrostenotic Crohn's Disease

Phase: Phase 2
Age range: 18 Years and older
Enrollment: 320 participants

1 recruiting site

Updated Aug 24, 2026

Recruiting

NCT06226883

MORF-057 for Adults With Moderately to Severely Active Crohn’s Disease

A Phase 2 study of oral MORF-057 versus placebo in adults with moderately to severely active Crohn’s disease.

Crohn's Disease · Inflammatory Bowel Diseases

Phase: Phase 2
Age range: 18 Years–85 Years
Enrollment: 385 participants

223 recruiting sites

Updated Aug 21, 2026

Recruiting

NCT06430801

Phase 3 Tulisokibart Study for Moderate to Severe Crohn's Disease

A Phase 3 study comparing tulisokibart with placebo in people with moderately to severely active Crohn's disease.

Crohn's Disease

Phase: Phase 3
Age range: 16 Years–80 Years
Enrollment: 1,200 participants

457 recruiting sites

Updated Aug 21, 2026

Recruiting

NCT06636656

BI 3032950 for Adults With Moderate to Severe Ulcerative Colitis

A phase 2 study of intravenous then injected BI 3032950 in adults with ulcerative colitis whose prior targeted treatment was unsuccessful or stopped.

Ulcerative Colitis

Phase: Phase 2
Age range: 18 Years–80 Years
Enrollment: 80 participants

41 recruiting sites

Updated Aug 21, 2026

Recruiting

NCT06937086

Mirikizumab With Tirzepatide or Placebo for Ulcerative Colitis and Higher Weight

A study of mirikizumab plus tirzepatide or placebo in adults with active ulcerative colitis and obesity or overweight.

Obesity or Overweight · Ulcerative Colitis

Phase: Phase 3
Age range: 18 Years–70 Years
Enrollment: 350 participants

188 recruiting sites

Updated Aug 21, 2026

Recruiting

NCT06937099

Mirikizumab With Tirzepatide or Placebo for Crohn's Disease and Higher Weight

This study compares mirikizumab plus tirzepatide with mirikizumab plus placebo in adults with active Crohn's disease and obesity or overweight.

Crohn's Disease · Obesity or Overweight

Phase: Phase 3
Age range: 18 Years–70 Years
Enrollment: 290 participants

184 recruiting sites

Updated Aug 21, 2026

Recruiting

NCT07186101

LY4268989 plus mirikizumab for adults with active ulcerative colitis

A Phase 2 study comparing LY4268989 plus mirikizumab with mirikizumab alone in adults with moderately to severely active ulcerative colitis.

Ulcerative Colitis

Phase: Phase 2
Age range: 18 Years–80 Years
Enrollment: 252 participants

146 recruiting sites

Updated Aug 21, 2026

Recruiting

NCT07415044

Oral LY4268989 for Adults With Moderately to Severely Active Ulcerative Colitis

A Phase 2 study of oral LY4268989 versus placebo in adults with moderately to severely active ulcerative colitis.

Ulcerative Colitis, Active Moderate · Ulcerative Colitis, Active Severe · Ulcerative Colitis (UC)

Phase: Phase 2
Age range: 18 Years–80 Years
Enrollment: 1,431 participants

255 recruiting sites

Updated Aug 21, 2026

Recruiting

NCT07463183

MK-8690 for Adults With Moderately to Severely Active Ulcerative Colitis

A Phase 2 study comparing injected MK-8690 with placebo in adults with moderately to severely active ulcerative colitis.

Colitis Ulcerative · Ulcerative Colitis

Phase: Phase 2
Age range: 18 Years–75 Years
Enrollment: 100 participants

28 recruiting sites

Updated Aug 21, 2026

Recruiting

NCT06274554

Fluconazole With IL-23 Therapy for Adults With Crohn’s Disease

This study compares fluconazole with placebo alongside IL-23 therapy in adults with mild to moderate Crohn’s disease.

Crohn's Disease · Inflammatory Bowel Diseases

Phase: Phase 3
Age range: 18 Years and older
Enrollment: 120 participants

1 recruiting site

Updated Aug 20, 2026

Recruiting

NCT06819878

Phase 3 Afimkibart Study for Moderately to Severely Active Crohn’s Disease

A Phase 3 study comparing afimkibart with placebo in people with moderately to severely active Crohn’s disease.

Moderately to Severely Active Crohns Disease

Phase: Phase 3
Age range: 16 Years–80 Years
Enrollment: 600 participants

361 recruiting sites

Updated Aug 20, 2026

Recruiting

NCT07184996

Duvakitug Induction Study for Moderate-to-Severe Ulcerative Colitis

A Phase 3 study of duvakitug in people with moderately to severely active ulcerative colitis.

Ulcerative Colitis

Phase: Phase 3
Age range: 16 Years–80 Years
Enrollment: 980 participants

219 recruiting sites

Updated Aug 20, 2026

Recruiting

NCT07665723

Afimkibart and Medicine Processing in Adults With Active Ulcerative Colitis

A Phase 1 study of how afimkibart affects medicine processing in adults with moderately to severely active ulcerative colitis.

Active Ulcerative Colitis

Phase: Phase 1
Age range: 18 Years–60 Years
Enrollment: 25 participants

17 recruiting sites

Updated Aug 20, 2026

Recruiting

NCT03167437

Vorinostat and Ustekinumab for Moderate-to-Severe Colitis

Vorinostat and possible ustekinumab maintenance are studied in adults with moderate-to-severe Crohn’s disease, ulcerative colitis, or chronic granulomatous disease colitis.

Crohn's Disease

Phase: Phase 1, Phase 2
Age range: 18 Years–65 Years
Enrollment: 35 participants

1 recruiting site

Updated Aug 18, 2026